Mar 11, 2024 7:00 am EDT MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
Mar 07, 2024 7:13 am EST Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
Mar 07, 2024 6:00 am EST MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
Mar 01, 2024 9:00 am EST MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
Feb 22, 2024 7:00 am EST MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
Feb 07, 2024 7:00 am EST MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
Dec 14, 2023 7:30 am EST MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder